Considering Stage I cases only (n = 80), the hazard ratios for subsequent serous carcinoma, relative to wildtype SBTs, were 0.15 (CI 0.02 – 1.11) for BRAF-mutated SBTs and 1.19 (CI 0.22 – 6.45) for KRAS-mutated SBTs; considering Stage >I cases only (n = 120), the hazard ratios were 0.52 (CI 0.13 – 2.19) for BRAF-mutated SBTs and 0.79 (CI 0.28 – 2.21) for KRAS-mutated SBTs. The gene discussed is KRAS; the disease is serous adenocarcinoma.